share_log

东吴证券4月24日发布研报称，给予恒瑞医药（600276.SH）买入评级。评级理由主要包括：1）创新成果持续兑现，驱动业绩稳步增长；2）海外授权和海外临床收获不断，稳步推进国际化进程；3）早期研发能力突出，多个创新技术平台有望不断产出新产品。（每日经济新闻）

Dongwu Securities released a research report on April 24 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) continuous implementation of innovative results, driving steady growth in perfo

Zhitong Finance ·  Apr 24 15:14
Dongwu Securities released a research report on April 24 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) continuous implementation of innovative results, driving steady growth in performance; 2) continuous overseas licensing and overseas clinical gains to steadily advance the internationalization process; 3) early R&D capabilities are outstanding, and multiple innovative technology platforms are expected to continuously produce new products. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment